The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | ASCO GI: updates in KEYNOTE-177, IMbrave150 & ClarIDHy
Shahid Ahmed, PhD, MD, FRCPC, FACP, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada, provides an overview on updated trial data presented at this years American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including an updated analysis of KEYNOTE-177 (NCT02563002), evaluating pembrolizumab in colorectal cancer, as well as the updated overall survival data of the IMbrave150 trial (NCT03434379) evaluating atezolizumab in combination with bevacizumab compared with sorafenib in patients with untreated locally advanced or metastatic hepatocellular carcinoma. Finally, Dr Ahmed touches on the updated results from the ClarIDHy trial (NCT02989857) evaluating ivosidenib in patients with cholangiocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
